Losartan Potassium Tablet, Film Coated
Product Images NDC 71335-1235

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 71335-1235). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351235)

Label for Losartan Potassium 100 mg tablet by Bryant Ranch Prepack. The label includes storage instructions, a lot number, barcode, and a comparison reference to Cozaar 100 mg tablet by Aurobindo Pharma Limited. The package contains 30 tablets and states 'RX Only.'*

FDA Label Image

Figure1 (Losartan Fig1)

A line graph comparing the percentage of patients with a primary endpoint over study months for Losartan Potassium and Atenolol. The graph shows trends for both treatments up to 66 months, indicating a statistical adjustment with a reported risk reduction of 13% and a p-value of 0.021.*

FDA Label Image

Figure2 (Losartan Fig2)

A line graph showing the percentage of patients with fatal or non-fatal stroke over study months comparing Atenolol (dotted line) and Losartan Potassium (solid line). The graph includes a note on adjusted risk reduction of 25%, with a p-value of 0.001.*

FDA Label Image

Figure 3 (Losartan Fig3)

A figure titled 'Primary Endpoint Events within Demographic Subgroups' presenting hazard ratios with 95% confidence intervals for Losartan Potassium versus Atenolol. The chart compares event rates for primary composite and stroke (fatal/non-fatal) outcomes across subgroups defined by age, gender, race, ISH, diabetes, and history of cardiovascular disease, showing points and confidence intervals indicating favorability towards Losartan Potassium or Atenolol.*

FDA Label Image

Figure-4 (Losartan Fig4)

A line graph comparing the percentage of patients with an event over months between Losartan Potassium and placebo groups. The graph shows cumulative incidence over 48 months, indicating a risk reduction of 16.1% with Losartan Potassium (p=0.022). The solid line represents Losartan Potassium, and the dashed line represents placebo.*

FDA Label Image

Chemical Structure (Losartan Str)

Chemical structure diagram of Losartan Potassium, showing its molecular framework including a chlorinated biphenyl group and a tetrazole ring, consistent with the active ingredient Losartan Potassium.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.